Deal Ticker: Kellerhals Carrard advises TecMed on the Acquisition of Ypsomed Diabetes Care to Build Global Insulin Powerhouse

TecMed is taking a step towards becoming a global diabetes care leader fully focused on innovative insulin infusion systems. The Burgdorf-based company, controlled by Willy Michel, has signed an agreement to acquire Ypsomed’s renowned diabetes care business for CHF 420 million. The deal is expected to close in the second half of 2025.

With this acquisition, TecMed will combine Ypsomed’s cutting-edge mylife Loop system – including the YpsoPump and the advanced AID solution CamAPS FX – with its own patch pump program. The goal: to offer diabetes patients worldwide the most innovative, flexible, and effective insulin infusion therapies.

“Our vision is clear: to empower persons with diabetes through choice and innovation in their therapy options," says Patrick Schär, current CEO and designated Chief Corporate Services Officer of TecMed AG. «The experience of Ypsomed Diabetes Care as a pioneer in insulin pump therapy will be the ideal set-up for the future launch of our patch-pump.” A new headquarters for 250 employees is already under construction in Burgdorf.

Kellerhals Carrard advised TecMed as lead counsel on this strategic transaction. The team is led by Beat Brechbühl and included specialists across M&A (Marc Hanslin, Patric Brand, Roman Aus der Au, Danijel Gajic), life sciences (Jörg von Manger-Koenig), antitrust (Daniel Emch, Stefanie Karlen), IP (Eliane Haas), employment (Bettina Achermann), data protection (Milena Grob), and real estate (Livio Marelli).